Total
0
Shares
Medlab (ASX:MDC)- CEO, Sean Hall - The Market Herald
CEO, Sean Hall
Source: Medlab
  • Biotech company Medlab Clinical (MDC) has been granted an Australian patent for its NanoCelle delivery platform
  • Essentially, NanoCelle delivers drug formulations via an oral spray
  • So far, product testing results have indicated the spray can lead to better absorption of the drugs, helping the formulation avoid ingested routes
  • It can also potentially lower drug dosages and reduce the side effects of some formulations
  • Medlab has also filed patent applications in other jurisdictions, such as the U.S., Europe and New Zealand
  • On the market this afternoon, Medlab is up 3.03 per cent, trading for 17 cents per share

Biotech company Medlab Clinical (MDC) has been granted an Australian patent for its NanoCelle delivery platform.

Essentially, NanoCelle delivers drugs via an oral spray. The device sprays the formulation into the Oro-buccal membrane, which is located along the lining of the cheek and the roof of the mouth.

So far, product testing results have indicated the spray can lead to better absorption of the drugs, helping the formulation avoid ingested routes. It can also potentially lower drug dosages and reduce the side effects of some formulations

Source: Medlab

Medlab CEO, Sean Hall, is pleased with the patent and says NanoCelle is a key feature in Medlab's leading drug, NanaBis.

"This is the first patent granted for our NanoCelle drug delivery platform, it is a huge validation of the science behind NanoCelle and its innovative mode of action," he said.

"NanoCelle is used to greatly improve drug solubility issues resulting in improved absorption, metabolism and utilisation, giving us [Medlab] many options to improve prescription and over the counter medicines," he added.

Medlab has also filed patent applications in the U.S., Europe, New Zealand, Canada, Hong Kong and Singapore.

On the market this afternoon, Medlab is up 3.03 per cent, trading for 17 cents per share at 2:06 pm AEST.


Subscribe


MDC by the numbers
More From The Market Herald
Cleanspace (ASX: CSX) - CEO, Dr Alex Birrell - The Market Herald

" CleanSpace (ASX:CSX) shares soar on ASX listing

CleanSpace (CSX) has today listed on the Australian Securities Exchange (ASX) with an initial market capitalisation of $339.7 million.
PainChek (ASX:PCK)- CEO, Philip Daffas (left) - The Market Herald

" PainChek (ASX:PCK) signs partnership deal with disability service provider

PainChek (PCK) has signed its first partnership with a disability service provider Nulsen Group.
Proteomics International Laboratories (ASX:PIQ) - Managing Director, Dr Richard Lipscombe - The Market Herald

" Proteomics International (ASX:PIQ) to raise $6M for high-tech blood test

Proteomics International (PIQ) has received firm commitments to undertake a $6 million share placement.
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald

" Immutep’s (ASX:IMM) efti drug to be tested against COVID-19

A novel cancer immunotherapy developed by Immutep (IMM) will be tested in an investigator-initiated clinical trial against COVID-19.